Close

Form 15-12B Trillium Therapeutics

November 29, 2021 6:31 AM EST

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number

001-36596

 

TRILLIUM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

c/o Trillium Therapeutics USA Inc.

100 CambridgePark Drive, Suite 510

Cambridge, Massachusetts 01240

(416) 595-0627

 

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Common Shares, no par value per share

 

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     
Rule 12g-4(a)(1)   x
Rule 12g-4(a)(2)   ¨
Rule 12h-3(b)(1)(i)   x
Rule 12h-3(b)(1)(ii)   ¨
Rule 15d-6   ¨
Rule 15d-22(b)   ¨

 

Approximate number of holders of record as of the certification or notice date: 1

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Trillium Therapeutics Inc. has caused this certification and notice to be signed on its behalf by the undersigned duly authorized person.

 

 

 

 

 

 

Date: November 29, 2021   TRILLIUM THERAPEUTICS INC.    
   
  By: /s/ Andrew Muratore
  Name: Andrew Muratore  
  Title: Vice President

 

  

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings